STOCK TITAN
  1. Home
  2. News
  3. DMAC

DiaMedica Therapeutics Inc - DMAC STOCK NEWS

Welcome to our dedicated news page for DiaMedica Therapeutics (Ticker: DMAC), a resource for investors and traders seeking the latest updates and insights on DiaMedica Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DiaMedica Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DiaMedica Therapeutics's position in the market.

News
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Rhea-AI Summary
DiaMedica Therapeutics announced the first patient dosed in the relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for acute ischemic stroke treatment. The trial aims to enroll 350 patients at 100 global sites, with U.S. sites expected to be activated by Q3 2024. Canadian sites will start in Q3 2024, Australian in Q4 2024, and expansion to the UK, Spain, and other European countries planned. The company is optimistic about the progress and quality of activated sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) provides a business update and financial results for the year ended December 31, 2023. The company has commenced ReMEDy2 clinical site activation and strengthened its management team. With $53 million in cash, DiaMedica has runway till 2026. The ReMEDy2 Phase 2/3 AIS clinical developments are progressing well with multiple sites opened in the U.S. and plans for global expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
earnings
-
News
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) presents the protocol and rationale for ReMEDy2, a pivotal trial in patients suffering from acute ischemic stroke. The company announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
none
News
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Rhea-AI Summary
DiaMedica Therapeutics Inc. (DMAC) appoints Dr. Lorianne Masuoka, a board-certified neurologist with over 25 years of experience, as Chief Medical Officer. Dr. Masuoka has a successful track record in managing clinical programs and progressing the development of therapeutics for neurological disorders. The company granted her an inducement stock option to purchase 285,000 shares of DiaMedica's common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
management
-
News
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announces an updated amendment to the ReMEDy2 AIS protocol aimed at enhancing patient enrollment and increasing the probability of study success. The 30-day FDA review period passed without comment. The company has $56 million in cash with a runway to 2026. A conference call on November 14 will discuss the business update and financial results for the quarter ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.84%
Tags
earnings
-
News
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) to participate in 14th Annual Craig-Hallum Alpha Select Conference in New York on November 16, 2023, offering investors the opportunity to schedule meetings with company management. Key focus on developing recombinant KLK1 (DM199) for acute ischemic stroke treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
News
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2023 financial results on November 13th. The company will host a conference call on November 14th at 7:00 AM CT to provide a business update and discuss financial results. Interested parties can access the call through web access or dial-in. The webcast will be available for playback on the company's website for 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences earnings
-
News
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
Rhea-AI Summary
DiaMedica Therapeutics appoints Ambarish Shah as Chief Technology Officer for the development of manufacturing operations for DM199 drug candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
management
-
News
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
Rhea-AI Summary
DiaMedica Therapeutics CEO to participate in Lake Street Capital Market's conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.5%
Tags
conferences
News
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
DiaMedica Therapeutics resumes ReMEDy2 clinical trial after FDA lifts clinical hold. Completed $37.5M private placement. Cash runway into 2026. Completed additional safety cohort of ACEi patients in Phase 1C study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
earnings
Stock DMAC logo
DiaMedica Therapeutics Inc

Nasdaq:DMAC

DMAC Rankings

#4333 Ranked by Market Cap
#184 Ranked by Stock Gains
N/A Ranked by Dividends

DMAC Stock Data

92.24M
23.82M
26.71%
22.01%
0.53%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Minneapolis

About DMAC

diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.